Preclinical versus clinical drug combination studies Journal Article


Author: Chou, T. C.
Article Title: Preclinical versus clinical drug combination studies
Abstract: This brief review provides a practical guide for drug combination studies and delineates its essence in terms of the mass-action-based theory, experimental design and automated computerised data analysis. The combination index (CI) method of Chou-Talalay is based on the multiple drug effect equation derived from the median-effect principle of the mass-action law. It provides quantitative determination for synergism (CI < 1), additive effect (CI = 1) and antagonism (CI < 1), and provides the algorithm for computer software for automated simulation for drug combinations. It takes into account both the potency (the Dm value) and the shape of the dose-effect curve (the m value) of each drug alone and their combination. The best feature is that it allows for small size experiments. The automated computer simulation reveals whether there is a synergism, determines how much synergism (the CI value) at any effect levels (the Fa-CI plot), or at any dose levels (the isobologram), provides the information regarding how many folds of dose-reduction is allowed for each drug, at a given effect for a synergistic combination, comparing with the dose required for each drug alone (the Fa-DRI plot), and the optimal combination ratio and schedule dependency for synergy. The 'polygonogram' dissects the component drug interactions or projects the make-ups of cocktails in complicated combinations. Based on scientific, practical and ethical reasons, it is not possible to 'determine' synergism in humans, and thus prior to the drug combination clinical trials, preclinical drug combination studies in vitro and/or in animals should be carried out to obtain the basis and rationale for studies in humans.
Keywords: review; dose response; drug potentiation; methodology; antineoplastic agent; animals; antineoplastic combined chemotherapy protocols; drug potency; dose-response relationship, drug; drug evaluation, preclinical; algorithms; automation; models, theoretical; drug antagonism; drug research; quantitative analysis; data analysis; malignant neoplastic disease; computer simulation; computer program; drug interactions; research ethics; mathematical analysis; combination index and plot; compusyn software; computerised simulation of synergism and antagonism; dose-reduction index and plot; drug combination in vitro; in animals and in clinics; isobologram; mathematical induction-deduction; median-effect principle and plot; physico-chemical principle of the mass-action law; polygonogram
Journal Title: Leukemia and Lymphoma
Volume: 49
Issue: 11
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2008-01-01
Start Page: 2059
End Page: 2080
Language: English
DOI: 10.1080/10428190802353591
PUBMED: 19021049
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 26" - "Export Date: 17 November 2011" - "CODEN: LELYE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ting-Chao Chou
    319 Chou